Related Experiment Video
Updated: Jul 10, 2026
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Serum resistin concentrations in growth hormone-deficient children during growth hormone replacement therapy
Hiroki Nozue1, Tomohiro Kamoda, Akira Matsui
1Department of Pediatrics, Tsukuba Medical Center Hospital, Ibaraki 305-8558, Japan. nozueh@xd5.so-net.ne.jp
Insights
Growth hormone (GH) therapy in children with GH deficiency (GHD) increases serum resistin levels. However, this rise in resistin is not linked to changes in free fatty acids, suggesting a different metabolic response than in adults.
Area of Science:
- Pediatric Endocrinology
- Metabolic Research
- Hormone Therapy
Background:
- Growth hormone deficiency (GHD) affects children's growth and metabolism.
- Resistin is an adipokine implicated in metabolic regulation.
- The impact of growth hormone (GH) on resistin in GHD children is not well understood.
Purpose of the Study:
- To investigate the effect of recombinant human GH (hGH) on serum resistin concentrations in prepubertal GHD children.
- To assess the relationship between serum resistin and free fatty acid (FFA) levels during GH replacement therapy.
- To compare metabolic markers before and after short-term hGH treatment.
Main Methods:
- Study included 20 prepubertal GHD children (16 boys, 4 girls).
- Treatment involved recombinant human GH (hGH) for 1 month.
- Serum levels of resistin, IGF-I, FFA, triglycerides, cholesterol, glucose, leukocyte counts, and HbA1c were measured at baseline and after treatment.
Main Results:
- Serum resistin levels significantly increased after 1 month of hGH therapy (P < .05).
- Serum FFA levels showed no significant change before and after hGH treatment.
- No significant correlation was observed between serum resistin and FFA levels post-therapy.
Conclusions:
- Short-term hGH therapy in GHD children leads to elevated serum resistin levels.
- The observed increase in resistin is not associated with GH-induced lipolysis in this pediatric cohort.
- This suggests a distinct metabolic adaptation to GH therapy in children compared to adults.
Abstract:
We performed this study to examine whether the serum resistin concentrations in growth hormone (GH)-deficient (GHD) children are influenced by administration of GH and to assess the relationship between serum resistin and free fatty acid levels during GH replacement therapy. The study included 20 prepubertal GHD children (16 boys and 4 girls) who were treated with recombinant human GH (hGH). The serum levels of resistin, insulin-like growth factor I, free fatty acid (FFA), triglyceride, cholesterol and glucose levels, leukocyte counts, and hemoglobin A(1c) were measured at baseline and after 1 month of hGH treatment. The serum resistin levels after hGH therapy were significantly higher than the basal resistin levels (median [range], 6.2 [4.9-11.8] vs 5.6 [4.4-8.3] ng/mL; P < .05), whereas the serum FFA levels were unchanged before and after treatment (0.51 [0.34-0.76] vs 0.37 [0.24-0.60] mEq/L). No significant relationship was found between serum resistin and FFA levels after hGH therapy. Body mass index, serum triglyceride, cholesterol and glucose levels, leukocyte counts, and hemoglobin A(1c) showed no significant differences before and after hGH treatment. Our results suggest that elevated serum resistin levels after 1-month hGH therapy in GHD children are not associated with the GH-induced lipolysis as found in GHD adults during short-time hGH therapy.
